Skip to main content
. 2018 Oct 9;11:1669–1676. doi: 10.2147/IDR.S174913

Table 1.

Comparisons of characteristics between diabetic patients with community-acquired KP bacteremia who developed invasive syndrome and those who did not develop invasive syndrome

Characteristics, n (%) Invasive syndrome (%)
P-valuea
Yes (n=41) No (n=134)

K1/K2 serotype of KP 18 (43.9) 4 (3.0) <0.01b
Male 17 (41.5) 47 (35.1) 0.47
Age ≥60 years 19 (46.3) 65 (48.5) 0.86
Newly diagnosed diabetes 8 (19.5) 15 (11.2) 0.19
HbA1c ≤7% 4 (9.8) 29 (21.6) 0.11
HbA1c 7%–9% 5 (12.2) 32 (23.9) 0.13
HbA1c ≥9% 32 (78.0) 73 (54.4) 0.01b
Cardiovascular diseases 4 (9.8) 4 (3.0) 0.09
Liver cirrhosis 3 (7.3) 5 (3.7) 0.39
Chronic renal failure 8 (19.5) 21 (15.7) 0.64
Alcoholism 3 (7.3) 6 (4.5) 0.44
COPD 3 (7.3) 6 (4.5) 0.44
Malignancy 3 (7.3) 13 (9.7) 0.77
Biliary tract diseases 1 (2.4) 4 (3.0) >0.99
High-dose steroid use 3 (7.3) 6 (4.5) 0.44
Aspirin use 1 (2.4) 23 (17.1) 0.02b
Leukocytes, ×109/Lc 12.2 (4.4) 10.4 (4.4) 0.75
Platelets, ×109/Lc 178 (45) 202 (57) 0.87
C-reactive protein, mg/Lc 163 (97) 166 (85) 0.83

Notes:

a

There was adequate goodness of fit (Hosmer and Lemeshow test: χ2=0.50, P>0.99). ROC analysis indicated that the predictive performance of the logistic regression model was adequate (AUC=0.77).

b

Results of multivariate analysis indicated that diabetic patients with community-acquired KP bacteremia who were infected with strains expressing the K1/K2 serotype (AOR, 8.81; 95% CI, 2.18–35.53; P<0.01) and those with HbA1c ≥9% (AOR, 4.97; 95% CI, 1.73–14.23; P<0.01) were at increased risk of developing IKLAS, whereas those who had recent therapy with aspirin (AOR, 0.17; 95% CI, 0.04–0.79; P=0.02) were at a lower risk of acquiring IKLAS.

c

Data depicted are mean values with SD.

Abbreviations: KP, Klebsiella pneumonia; ROC, receiver operating characteristic; AUC, area under the curve; AOR, adjusted odds ratio; IKLAS, invasive Klebsiella pneumoniae liver abscess syndrome.